GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Establishment Labs Holdings Inc (NAS:ESTA) » Definitions » ROE %

Establishment Labs Holdings (Establishment Labs Holdings) ROE % : -336.19% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Establishment Labs Holdings ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Establishment Labs Holdings's annualized net income for the quarter that ended in Dec. 2023 was $-82.2 Mil. Establishment Labs Holdings's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $24.4 Mil. Therefore, Establishment Labs Holdings's annualized ROE % for the quarter that ended in Dec. 2023 was -336.19%.

The historical rank and industry rank for Establishment Labs Holdings's ROE % or its related term are showing as below:

ESTA' s ROE % Range Over the Past 10 Years
Min: -1537.75   Med: -68.24   Max: -65.45
Current: -493.26

During the past 8 years, Establishment Labs Holdings's highest ROE % was -65.45%. The lowest was -1,537.75%. And the median was -68.24%.

ESTA's ROE % is ranked worse than
98.15% of 809 companies
in the Medical Devices & Instruments industry
Industry Median: 0.25 vs ESTA: -493.26

Establishment Labs Holdings ROE % Historical Data

The historical data trend for Establishment Labs Holdings's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Establishment Labs Holdings ROE % Chart

Establishment Labs Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -69.94 -66.54 -65.46 -353.48 -1,537.75

Establishment Labs Holdings Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -344.57 -274.35 -336.19

Competitive Comparison of Establishment Labs Holdings's ROE %

For the Medical Devices subindustry, Establishment Labs Holdings's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Establishment Labs Holdings's ROE % Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Establishment Labs Holdings's ROE % distribution charts can be found below:

* The bar in red indicates where Establishment Labs Holdings's ROE % falls into.



Establishment Labs Holdings ROE % Calculation

Establishment Labs Holdings's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-78.502/( (-8.185+18.395)/ 2 )
=-78.502/5.105
=-1,537.75 %

Establishment Labs Holdings's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-82.168/( (30.487+18.395)/ 2 )
=-82.168/24.441
=-336.19 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Establishment Labs Holdings  (NAS:ESTA) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-82.168/24.441
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-82.168 / 126.24)*(126.24 / 269.587)*(269.587 / 24.441)
=Net Margin %*Asset Turnover*Equity Multiplier
=-65.09 %*0.4683*11.0301
=ROA %*Equity Multiplier
=-30.48 %*11.0301
=-336.19 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-82.168/24.441
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-82.168 / -92.188) * (-92.188 / -88.46) * (-88.46 / 126.24) * (126.24 / 269.587) * (269.587 / 24.441)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.8913 * 1.0421 * -70.07 % * 0.4683 * 11.0301
=-336.19 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Establishment Labs Holdings ROE % Related Terms

Thank you for viewing the detailed overview of Establishment Labs Holdings's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Establishment Labs Holdings (Establishment Labs Holdings) Business Description

Traded in Other Exchanges
Address
Coyol Free Zone, Building B15 and 25, Alajuela, CRI
Establishment Labs Holdings Inc is a medical technology company engaged in offering medical devices and aesthetic products. It is involved in designing, manufacturing, and marketing silicone-filled breast and body shaping implants. The company markets its products under Motiva implants Brand. It distributes its products to medical distributors; and physicians, hospitals, and clinics in the form of direct sales. Its geographical segments are Europe, Latin America, Asia-Pacific/Middle East, and Others.
Executives
Nicholas Sheridan Lewin director, 10 percent owner 3 WEST 57TH ST., 8TH FLOOR, NEW YORK NY 10019
Raj Denhoy officer: Chief Financial Officer C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Dennis E Condon director 811 ALSTON RD, SANTA BARBARA CA 93108
Leslie Gillin director C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Paul D. Rodio officer: Chief Operating Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Samuel Ross Mansbach other: GC & Chief Compliance Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Jw Asset Management, Llc 10 percent owner, other: See Footnote(1) 1051 N VENETIAN DRIVE, MIAMI BEACH FL 33139
Bryan Slotkin director C/O MOTIVA USA,.LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Ann Custin director C/O MOTIVA USA, LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Edward J Schutter director C/O FIRST HORIZON PHARMACEUTICAL CORP, 6195 SHILOH ROAD, ALPHARETTA GA 30005
Lisa Gersh director C/O HASBRO, INC., 1011 NEWPORT AVENUE, PAWTUCKET RI 02861
Mezerville Roberto De officer: Chief Technology Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Renee Gaeta officer: Chief Financial Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958
Pratip Dastidar officer: Head of Global Operations 150 PEABODY PLACE, MEMPHIS TN 38103
Santos Salvador Dada officer: Chief Operating Officer C/O MOTIVA USA LLC, 16192 COASTAL HIGHWAY, LEWES DE 19958